Transdermal Scopolamine

PUBLISHED: May 20, 2024

PAGES: 194 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Transdermal Scopolamine Market to Reach $630.5 Million by 2030

The global market for Transdermal Scopolamine estimated at US$440.2 Million in the year 2023, is expected to reach US$630.5 Million by 2030, growing at a CAGR of 5.3% over the period 2023-2030.

The U.S. Market is Estimated at $133.3 Million, While China is Forecast to Grow at 5% CAGR

The Transdermal Scopolamine market in the U.S. is estimated at US$133.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$110.7 Million by the year 2030 trailing a CAGR of 5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 41 Featured) -

Alchem International
Alkaloids of Australia
ALZA Corporation
Baxter International Inc.
Caleb Pharmaceuticals Inc
Centroflora-Cms
Fine Chemicals Corporation
GlaxoSmithKline Plc
Myungmoon Pharma Co. Ltd.
Novartis AG
Perrigo Co. Plc
Phytex Australia

Product Code: MCP16073

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Transdermal Scopolamine - Global Key Competitors Percentage Market Share in 2024 (E)
- Global Economic Update
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 2: World Historic Review for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 3: World 16-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 4: World Transdermal Scopolamine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
- Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 5: USA Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 6: USA Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
CANADA
- TABLE 7: Canada Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 8: Canada Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
JAPAN
- Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 9: Japan Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 10: Japan Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
CHINA
- Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 11: China Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 12: China Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
EUROPE
- Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 13: Europe Recent Past, Current & Future Analysis for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 14: Europe Historic Review for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 15: Europe 16-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
FRANCE
- Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 16: France Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 17: France Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
GERMANY
- Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 18: Germany Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 19: Germany Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
ITALY
- TABLE 20: Italy Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 21: Italy Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
UNITED KINGDOM
- Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 22: UK Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 23: UK Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF EUROPE
- TABLE 24: Rest of Europe Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 25: Rest of Europe Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
ASIA-PACIFIC
- Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 27: Asia-Pacific Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF WORLD
- TABLE 28: Rest of World Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 29: Rest of World Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR